NCT00050596已完成2 期
A Randomized Study Comparing 4 Monthly Doses of MDX-010 (CTLA-4) as a Single Agent or Used in Combination With a Single Dose of Docetaxel in Patients With Hormone-Refractory Prostate Cancer
Bristol-Myers Squibb22 个研究点 分布在 1 个国家开始时间: 2002年11月最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 试验地点
- 22
研究概览
简要总结
The primary objectives of the study are to determine the safety and activity of multiple doses of MDX-010 in patients with hormone-refractory prostate cancer (HRPC), and to determine the safety and activity profile of a single dose of cytotoxic chemotherapy (docetaxel) in combination with MDX-010
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of adenocarcinoma of the prostate.
- •Metastatic prostate cancer (positive bone scan or measurable disease).
- •Progressive disease after androgen deprivation.
- •No prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control prostate cancer).
排除标准
- •Other prior malignancy, except for adequately treated basal or squamous cell skin cancer or superficial bladder cancer, or any other cancer from which the patient has been disease-free for greater than or equal to 5 years.
- •Previous occurrence of autoimmune disease.
- •Active infection requiring therapy including HIV or chronic hepatitis.
研究者
研究点 (22)
Loading locations...
相似试验
已完成
2 期
Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma SubjectsAsthmaNCT01772368Teva Branded Pharmaceutical Products R&D, Inc.72
已完成
1 期
Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult VolunteersHealthyNCT02228707Biogen56
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old InfantsHealthyNCT00686075MedImmune LLC1,338
终止
1 期
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788HealthyNCT02255968Enanta Pharmaceuticals, Inc16
终止
1 期
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's DiseaseAlzheimer's DiseaseNCT01677572Biogen197